Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Timeline

Start

2025-03-31

Primary completion

2028-06

Completion

2028-12

Drugs

Indications